Table 3.
Comparison of MS patients with and without relapses after SARS-CoV-2 vaccinations regarding demographic and clinical characteristics.
| PwMS | ||
|---|---|---|
| With Relapse after Vaccination (N = 244 *) | Without Relapse after Vaccination (N = 2414) | |
| Gender, N (%) | ||
| Female | 203 (83.5) | 1853 (77.4) |
| Male | 39 (16.0) | 534 (22.3) |
| Divers | 1 (0.4) | 8 (0.3) |
| Age [years], median | 41.9 | 45.6 |
| MS disease course, N (%) | ||
| RRMS | 206 (84.4) | 1781 (73.8) |
| SPMS | 28 (11.5) | 428 (17.7) |
| PPMS | 0 (0.0) | 99 (4.1) |
| Undefined | 10 (4.1) | 106 (4.4) |
| Disability level (PDDS), N (%) | ||
| Mild (0–1) | 133 (54.5) | 1243 (51.5) |
| Moderate (2–4) | 90 (36.9) | 873 (36.2) |
| Severe (≥5) | 21 (8.6) | 298 (12.3) |
| Coincident autoimmune disease, N (%) | 60 (24.6) | 510 (21.1) |
| DMD treatment, N (%) | 146 (60.1) | 1774 (73.5) |
| Relapse within the year prior to X1, N (%) | 69 (28.3) | 322 (13.3) |
| Relapse within 6 months prior to X1, N (%) | 43 (17.6) | 170 (7.0) |
| Relapse within 3 months prior to X1, N (%) | 18 (7.4) | 82 (3.4) |
| Time from last relapse (before X1) to X1 [years], median (range) | 1.4 (0.05–24.2) | 3.3 (0.03–40.7) |
DMD, disease-modifying drug; MS—multiple sclerosis; N—number of patients; PDDS—patient-determined disease steps; PPMS—primary progressive MS; PwMS—people with MS; RRMS—relapsing–remitting MS; SARS-CoV-2—severe acute respiratory syndrome coronavirus 2; SPMS—secondary progressive MS; X1—first SARS-CoV-2 vaccination; *—three patients were excluded from this analysis due to implausibility.